Company news

Share this article:
Amylin has announced a corporate restructuring that will result in a reduction of workforces by 25%, or 340 employees. “Sales revenues have not met the expectations we had when we scaled up our organization,” said Daniel Bradbury, president and CEO at Amylin, in a statement.
 
A Pfizer manufacturing plant in Indiana has been put up for sale. The plant most recently manufactured Exubera, an inhaled insulin therapy, which didn't catch on with patients.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.